Abstract：Objective To explore the factors related to anemia in patients with newly diagnosed malignant solid tumors.Methods The clinical data on 401 newly diagnosed patients with malignant solid tumors admitted to our department between May 2014 and May 2019 was reviewed. The effect of gender, age, types of tumors, tumor stage,KPS scores, albumin, cholesterol, C-reactive protein (CRP) and ferritin on the occurrence of anemia was analyzed.Results Among the 401 patients, 224 were males (55.9%), 177 were females (44.1%), the median age was 71 years (28-95 years), and 251 (62.6%) were diagnosed with anemia. Univariate analysis showed that age over 60, urinary system tumors, tumor stage Ⅳ, a KPS score <70 points, albumin <40 g/L, normal cholesterol levels, and elevated CRP and ferritin levels could increase the chance of anemia (P<0.05). Multivariate logistic regression analysis showed that hypoalbuminemia(OR=6.981,95%CI 3.914-12.450) and KPS score <70(OR=1.835,95%CI 1.028-3.274) were independent risk factors for anemia in patients with newly diagnosed malignant solid tumors. KPS scores and serum levels of albumin and cholesterol were positively correlated with hemoglobin concentrations, while age, CRP and ferritin levels were negatively correlated.Conclusions The incidence of anemia in newly diagnosed patients with malignant solid tumors is high, which has different causes. Hypoalbuminemia and a KPS score <70 are independent risk factors for anemia in patients with newly diagnosed malignant solid tumors.
Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature[J]. Am J Med, 2004,116 (Suppl 7A):11S-26S.
Gascon P, Rodriguez C A, Valentin V, et al. Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study[J]. Support Care Cancer, 2013,21(11):3039-3049.
[5]
Littlewood T J. Management options for cancer therapy-related anaemia[J]. Drug Saf, 2002,25(7):525-535.
[6]
Watine J, Bouarioua N. Anemia as an independent prognostic factor for survival in patients with cancer[J]. Cancer, 2002,94(10):2793-2797.
[7]
Qiu M Z, Xu R H, Ruan D Y, et al. Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China[J]. Tumour Biol, 2010,31(6):633-641.
[8]
Paitan V, Alcarraz C, Leonardo A, et al. Anemia as a prognostic factor in cancer patients[J]. Rev Peru Med Exp Salud Publica, 2018, 35(2): 250-258.
[9]
Ludwig H, Van Belle S, Barrett-Lee P, et al. The european cancer anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients[J]. Eur J Cancer, 2004, 40(15): 2293-2306.
[10]
Maccio A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study[J]. Haematologica, 2015, 100(1): 124-132.
Hung S C, Tung T Y, Yang C S, et al. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients[J]. Am J Kidney Dis, 2005, 45(6):1073-1083.
[15]
Adamson J W. The anemia of inflammation/malignancy: mechanisms and management[J]. ASH Education Program Book, 2008, 2008(1): 159-165.
[16]
Weiss G, Goodnough L T. Anemia of chronic disease[J]. N Engl J Med, 2005,352(10):1011-1023.
[17]
Madu A J, Ughasoro M D. Anaemia of chronic disease: an in-depth review[J]. Med Princ Pract, 2017, 26(1):1-9.
[18]
Falkensammer C E, Thurnher M, Leonhartsberger N, et al. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival[J]. BJU Int, 2011, 107(12):1893-1898.
[19]
Rossi E. Hepcidin--the iron regulatory hormone[J]. Clin Biochem Rev, 2005, 26(3): 47-49.
[20]
Singh B, Arora S, Agrawal P, et al. Hepcidin: a novel peptide hormone regulating iron metabolism[J]. Clin Chim Acta, 2011, 412(11-12): 823-830.
[21]
Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation[J]. Blood, 2003, 102(3):783-788.
[22]
Andriopoulos B J, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism[J]. Nat Genet, 2009, 41(4):482-487.
[23]
Park C H, Valore E V, Waring A J, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver[J]. J Biol Chem, 2001, 276(11):7806-7810.
[24]
Wrighting D M, Andrews N C. Interleukin-6 induces hepcidin expression through STAT3[J]. Blood, 2006, 108(9): 3204-3209.
[25]
Maccio A, Madeddu C, Massa D, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia[J]. Blood, 2005, 106(1):362-367.
[26]
Blay J Y, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma[J]. Cancer Res, 1992, 52(12): 3317-3322.
2021, Vol. 32 
